Basiliximab
Indications
Basiliximab is used for:
Acute graft rejection in renal transplantation
Adult Dose
Intravenous
Prophylaxis of Renal Transplant Rejection
20 mg IV within 2 hr prior to transplant surgery, THEN
20 mg IV 4 days after transplant
Used in regimen containing cyclosporine and corticosteroids
Child Dose
Prophylaxis of Renal Transplant Rejection
>35 kg: Administer as in adults; 20 mg IV within 2 hr prior to transplant surgery, THEN, 20 mg IV 4 days after transplant
<35 kg: 10 mg IV within 2 hr prior to transplant surgery, THEN 10 mg IV 4 days after transplant
Used in regimen containing cyclosporine and corticosteroids
Renal Dose
Administration
IV Preparation
Reconstitute vials with 5 mL SWI
Dilute reconstituted contents in 50 mL NS or D5W
IV Administration
For central or intravenous administration only
Infuse over 20-30 min
Contra Indications
Hypersensitivity to basiliximab and murine proteins.
Precautions
Pregnancy and lactation. Re-exposure to a subsequent course of therapy of basiliximab.
Lactation: Unknown whether excreted in milk; because of the potential for adverse reactions, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother
Pregnancy-Lactation
Interactions
Immunosuppressives other than ciclosporin and corticosteroids may increase the potential for over-immunosuppression.
Adverse Effects
Side effects of Basiliximab :
Peripheral oedema, hypertension, atrial fibrillation; fever, headache, insomnia, pain; wound complication, acne; hypokalaemia, hyperglycaemia, hyperuricaemia, hypophosphataemia, hypercholesterolaemia; GI effects; UTI; anaemia; tremor; dyspnoea, infection.
Rarely, hypersensitivity and anaphylactoid-type reactions.
Mechanism of Action
Basiliximab, a chimeric murine/human monoclonal antibody, blocks the ?-chain of the interleukin-2 receptor complex on the surface of activated T-lymphocytes.